Page 204 - Drug Class Review
P. 204
Page 132 of 205
Drug Effectiveness Review Project
placebo 75.1 60 NR 2.5 24.3 Primary Outcome Measures: Change from baseline to end point on the modified ADAS-cog total score Secondary Outcome Measures: Change from baseline on the MMSE; CDR-Sum of Boxes; CMBT; Significant improvement over placebo was observed in the donepezil group at endpoint on the modified Significant improvement over placebo was observed in the donepezil group (+1.8 points) at Significant improvement over placebo was observed in the donepezil group at endpoint on the following CMBT tasks: name-face association delayed recall (P = 0.04),
Groups similar at baseline: Yes
Alzheimer classification: Mild
donepezil 73.3 50 NR 2.9 24.1 Timing of assessments: Screening, baseline, every 6 weeks Health Outcome Measures: ADAS-cog total score (difference 2.3 points); P = 0.001 Intermediate Outcome Measures: endpoint on MMSE scores (P = 0.002) other CMBT scales
Apathy Scale • • •
Final Report Update 1 Authors: Seltzer et al. Year: 2004 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: Other germane population qualities: Onset cognitive symptoms • (yrs) MMSE • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs
